Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 2/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | CCR3 | P51677 | 3/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 5/20 | 0.46 |
| ▸ | BCHE | P06276 | 3/20 | 0.46 |
| ▸ | BACE1 | P56817 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL956109 | 1.00 | KCNA3 (0.49) | KCNA3KCNH2CCR3HRH1ACHE | |
| Hydrochloric Acid SCHEMBL954585 | 0.99 | KCNA3 (0.48) | KCNA3KCNH2CCR3HRH1ACHE | |
| Hydrochloric Acid SCHEMBL954583 | 0.99 | KCNA3 (0.48) | KCNA3KCNH2CCR3HRH1ACHE | |
| SCHEMBL4186493 | 0.92 | KCNA3 (0.55) | KCNA3KCNH2CCR3HRH1ACHE | |
| Hydrochloric Acid SCHEMBL10360726 | 0.90 | KCNA3 (0.53) | KCNA3KCNH2CCR3HRH1ACHE | |
| SCHEMBL11235320 | 0.88 | KCNA3 (0.50) | KCNA3CCR3ACHEDRD2DRD3 | |
| SCHEMBL17189449 | 0.88 | HRH1 (0.43) | KCNA3KCNH2CCR3HRH1ACHE | |
| SCHEMBL11840783 | 0.87 | KCNA3 (0.41) | KCNA3KCNH2CCR3HRH1ACHE | |
| SCHEMBL17180867 | 0.87 | SIGMAR1 (0.50) | HRH1ACHEALDH1A1SIGMAR1 | |
| SCHEMBL955693 | 0.87 | SIGMAR1 (0.50) | HRH1ACHEALDH1A1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110028433-B | Preparation method of deuterium-labeled doxapram and metabolite thereof | 梯尔希（南京）药物研发有限公司 | 2022-06-28 | — | — | CN | claimed |
| CN-110028433-B | Preparation method of deuterium-labeled doxapram and metabolite thereof | 梯尔希（南京）药物研发有限公司 | 2022-06-28 | — | — | CN | disclosed |
| CN-110028433-B | Preparation method of deuterium-labeled doxapram and metabolite thereof | 梯尔希（南京）药物研发有限公司 | 2022-06-28 | — | — | CN | disclosed |
| EP-2121594-B1 | QUATERNARY AMMONIUM DIPHENYLMETHYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R & D IP LLC (US) | 2015-10-21 | — | — | EP | disclosed |
| US-8802856-B2 | Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-08-12 | — | — | US | disclosed |
| US-20140051864-A1 | QUATERNARY AMMONIUM DIPHENYLMETHYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-8592453-B2 | Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2013-11-26 | — | — | US | disclosed |
| US-8378121-B2 | Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-8080565-B2 | Substituted 4-amino-benzylpiperidine compounds | THERAVANCE, INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-8030502-B2 | Muscarinic M2 receptor antagonists; such as 4-{N-[7-(3-1-carbamoyl-1,1-diphenylmethyl)pyrrolidin-1-yl)hept-1-yl]-N-(isopropyl)amino}-1-(4-methoxypyrid-3-ylmethyl)piperidine; reduced blurred vision, constipation and dry mouth side effects | THERAVANCE, INC. (US) | 2011-10-04 | — | — | US | disclosed |
| EP-0900787-B1 | PROCESS FOR PREPARING PYRROLIDINE DERIVATIVES | KANEKA CORP (JP) | 2002-09-11 | — | — | EP | disclosed |
| US-6005119-A | Process for preparing pyrrolidine derivatives | KANEKA CORPORATION (JP) | 1999-12-21 | — | — | US | disclosed |
| EP-0900787-A1 | PROCESS FOR PREPARING PYRROLIDINE DERIVATIVES | KANEKA CORPORATION (JP) | 1999-03-10 | — | — | EP | disclosed |
| EP-0178947-B1 | 1-[(Aminoalkyl and aminoalkylamino)carbonyl and thiocarbonyl]-alpha,alpha-diarylpyrrolidine, piperidine and homopiperidineacetamides and acetonitriles | A.H. ROBINS COMPANY, INCORPORATED (US) | 1990-09-26 | — | — | EP | disclosed |
| US-4812452-A | ANTIARRHYTHMIA AGENTS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1989-03-14 | — | — | US | disclosed |
| US-4812451-A | ANTIARRHYTHMIA AGENTS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1989-03-14 | — | — | US | disclosed |
| US-4810703-A | ANTIARRHYTHMIA | A. H. ROBINS COMPANY, INCORPORATED (US) | 1989-03-07 | — | — | US | disclosed |
| US-4594343-A | FOR DEEP FAT FRYING VAT OIL; REMOVING CONTAMINANTS; RESTAURANTS | A.H. ROBINS COMPANY, INCORPORATED, A DE CORP. | 1986-06-10 | — | — | US | disclosed |
| EP-0178947-A2 | 1-[(Aminoalkyl and aminoalkylamino)carbonyl and thiocarbonyl]-alpha,alpha-diarylpyrrolidine, piperidine and homopiperidineacetamides and acetonitriles | A.H. ROBINS COMPANY, INCORPORATED (US) | 1986-04-23 | — | — | EP | disclosed |
| EP-0178946-A2 | 1-(Aminoalkyl)-alpha, alpha-diaryl pyrrolidine-piperidine- and homopiperidine- acetamides and acetonitriles | A.H. ROBINS COMPANY, INCORPORATED (US) | 1986-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051864-A1 | QUATERNARY AMMONIUM DIPHENYLMETHYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM5, CHRM1 | KCNA3 78/4885KCNH2 81/4885CCR3 1134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.